vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). ALBANY INTERNATIONAL CORP runs the higher net margin — 4.3% vs 1.6%, a 2.7% gap on every dollar of revenue. On growth, ALBANY INTERNATIONAL CORP posted the faster year-over-year revenue change (12.0% vs 5.0%). Over the past eight quarters, ALBANY INTERNATIONAL CORP's revenue compounded faster (1.2% CAGR vs -0.2%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AIN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $177.4M |
| Net Profit | $13.9M | $2.9M |
| Gross Margin | 31.1% | — |
| Operating Margin | 9.3% | 3.9% |
| Net Margin | 4.3% | 1.6% |
| Revenue YoY | 12.0% | 5.0% |
| Net Profit YoY | -21.5% | — |
| EPS (diluted) | $0.56 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $321.2M | $196.9M | ||
| Q3 25 | $261.4M | $179.5M | ||
| Q2 25 | $311.4M | $181.1M | ||
| Q1 25 | $288.8M | $168.9M | ||
| Q4 24 | $286.9M | $187.3M | ||
| Q3 24 | $298.4M | $168.6M | ||
| Q2 24 | $332.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $13.9M | — | ||
| Q3 25 | $-97.8M | $5.4M | ||
| Q2 25 | $9.2M | $-4.8M | ||
| Q1 25 | $17.4M | $4.8M | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $18.0M | $-143.5M | ||
| Q2 24 | $24.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 31.1% | 79.5% | ||
| Q3 25 | -19.1% | 80.9% | ||
| Q2 25 | 31.3% | 77.4% | ||
| Q1 25 | 33.4% | 79.7% | ||
| Q4 24 | 31.5% | 78.7% | ||
| Q3 24 | 30.3% | 76.9% | ||
| Q2 24 | 33.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 9.3% | 1.2% | ||
| Q3 25 | -44.6% | 3.5% | ||
| Q2 25 | 7.2% | 4.7% | ||
| Q1 25 | 9.8% | 1.2% | ||
| Q4 24 | 8.5% | 13.2% | ||
| Q3 24 | 8.4% | -82.8% | ||
| Q2 24 | 12.9% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | -37.4% | 3.0% | ||
| Q2 25 | 2.9% | -2.7% | ||
| Q1 25 | 6.0% | 2.8% | ||
| Q4 24 | 6.2% | — | ||
| Q3 24 | 6.0% | -85.1% | ||
| Q2 24 | 7.4% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.56 | $0.05 | ||
| Q3 25 | $-3.37 | $0.12 | ||
| Q2 25 | $0.31 | $-0.11 | ||
| Q1 25 | $0.56 | $0.10 | ||
| Q4 24 | $0.57 | $0.38 | ||
| Q3 24 | $0.57 | $-3.11 | ||
| Q2 24 | $0.79 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $144.3M |
| Total DebtLower is stronger | $455.7M | — |
| Stockholders' EquityBook value | $726.2M | $653.9M |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | 0.63× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $112.3M | $238.4M | ||
| Q3 25 | $108.3M | $246.3M | ||
| Q2 25 | $106.7M | $445.9M | ||
| Q1 25 | $119.4M | $493.6M | ||
| Q4 24 | $115.3M | $484.6M | ||
| Q3 24 | $127.2M | $453.8M | ||
| Q2 24 | $116.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $455.7M | $372.2M | ||
| Q3 25 | $480.6M | $376.7M | ||
| Q2 25 | $444.7M | $580.5M | ||
| Q1 25 | $416.4M | $583.4M | ||
| Q4 24 | $318.5M | $585.3M | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $726.2M | $693.1M | ||
| Q3 25 | $739.3M | $727.2M | ||
| Q2 25 | $888.6M | $757.8M | ||
| Q1 25 | $900.0M | $798.5M | ||
| Q4 24 | $943.5M | $778.3M | ||
| Q3 24 | $991.0M | $749.6M | ||
| Q2 24 | $967.5M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.7B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.8B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.63× | 0.54× | ||
| Q3 25 | 0.65× | 0.52× | ||
| Q2 25 | 0.50× | 0.77× | ||
| Q1 25 | 0.46× | 0.73× | ||
| Q4 24 | 0.34× | 0.75× | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | — |
| Free Cash FlowOCF − Capex | $51.4M | — |
| FCF MarginFCF / Revenue | 16.0% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | 5.31× | — |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $73.7M | $43.7M | ||
| Q3 25 | $43.9M | $60.8M | ||
| Q2 25 | $32.7M | $12.0M | ||
| Q1 25 | $2.1M | $35.5M | ||
| Q4 24 | $78.5M | $33.1M | ||
| Q3 24 | $47.0M | $53.9M | ||
| Q2 24 | $83.4M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $51.4M | $43.5M | ||
| Q3 25 | $25.9M | $57.0M | ||
| Q2 25 | $18.8M | $9.3M | ||
| Q1 25 | $-13.5M | $26.9M | ||
| Q4 24 | $60.2M | $31.0M | ||
| Q3 24 | $31.6M | $49.8M | ||
| Q2 24 | $63.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 16.0% | 22.1% | ||
| Q3 25 | 9.9% | 31.7% | ||
| Q2 25 | 6.0% | 5.1% | ||
| Q1 25 | -4.7% | 15.9% | ||
| Q4 24 | 21.0% | 16.6% | ||
| Q3 24 | 10.6% | 29.6% | ||
| Q2 24 | 19.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.9% | 0.1% | ||
| Q3 25 | 6.9% | 2.2% | ||
| Q2 25 | 4.5% | 1.5% | ||
| Q1 25 | 5.4% | 5.1% | ||
| Q4 24 | 6.4% | 1.1% | ||
| Q3 24 | 5.2% | 2.4% | ||
| Q2 24 | 6.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 5.31× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 0.12× | 7.37× | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
